Alefacept is not associated with a reduced incidence of biopsy-confirmed acute T-cell-mediated rejection, say the authors of a recent randomized controlled trial. Rostaing et al. randomly assigned de novo renal transplant recipients to receive alefacept (n = 105) or placebo (n = 107). They found that memory-T-cell counts were decreased between 3 weeks and 6 months in the alefacept group, but found no difference in the incidence of acute T-cell-mediated rejection at 6 months. Patient and graft survival were similar in the two groups, as were safety and tolerability, although malignancy rate was higher in patients treated with alefacept.
ORIGINAL RESEARCH PAPER
Rostaing, L. et al. Alefacept combined with tacrolimus, mycophenolate mofetil and steroids in de novo kidney transplantation: a randomized controlled trial. Am. J. Transplant. doi:10.1111/ajt.12303
Rights and permissions
About this article
Cite this article
Alefacept does not reduce risk of T-cell-mediated rejection. Nat Rev Nephrol 9, 432 (2013). https://doi.org/10.1038/nrneph.2013.115
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.115